Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 24;26(13):6065.
doi: 10.3390/ijms26136065.

Immunopathology of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Katarzyna Aleksandra Lisowska  1 , Anna Wardowska  1
Affiliations
Review

Immunopathology of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Katarzyna Aleksandra Lisowska et al. Int J Mol Sci. .

Abstract

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) constitutes a group of rare diseases characterized by autoimmune-associated inflammation and vessel damage. Based on the clinical manifestations and involvement of immune components, three disease syndromes are distinguished: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). In this review, we present the current data on the epidemiology, the clinical manifestations of each syndrome, and the most up-to-date classification criteria. The role of the underlying genetic and epigenetic abnormalities, as well as their interplay, is described. The immunological diversification of AAV is also described, with a focus on the immune cell dysfunctions detected in patients. In conclusion, we emphasize the urgent need to unravel the sophisticated mechanisms of this disease, which would enable the development of new, effective therapeutic strategies.

Keywords: AAV; ANCA-associated vasculitis; EGPA; GPA; MPA; classification; epigenetic; genetic; immune cells; immunopathology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The course of AAV development.
See this image and copyright information in PMC

References

    1. Li J., Cui Z., Long J., Huang W., Wang J., Wang H., Zhang L., Chen M., Zhao M. The Frequency of ANCA-Associated Vasculitis in a National Database of Hospitalized Patients in China. Arthritis Res. Ther. 2018;20:226. doi: 10.1186/s13075-018-1708-7. - DOI - PMC - PubMed
    1. Berti A., Cornec D., Crowson C.S., Specks U., Matteson E.L. The Epidemiology of Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population–Based Study. Arthritis Rheumatol. 2017;69:2338–2350. doi: 10.1002/art.40313. - DOI - PMC - PubMed
    1. Coattrenec Y., Muller Y.D., Spoerl D., Lobrinus J.A., Seebach J.D. Prevalence of large vessel vasculitis in ANCA-associated vasculitis: A retrospective cohort study. Rheumatol. Int. 2021;41:2147–2156. doi: 10.1007/s00296-021-04993-2. - DOI - PMC - PubMed
    1. Kaymakci M.S., Elfishawi M.M., Langenfeld H.E., Hanson A.C., Crowson C.S., Bois M.C., Ghaffar U., Koster M.J., Specks U., Warrington K.J. Large vessel involvement in antineutrophil cytoplasmic antibody-associated vasculitis. Rheumatology. 2024;63:1682–1689. doi: 10.1093/rheumatology/kead467. - DOI - PubMed
    1. Cartin-Ceba R., Peikert T., Specks U. Pathogenesis of ANCA-Associated Vasculitis. Curr. Rheumatol. Rep. 2012;14:481–493. doi: 10.1007/s11926-012-0286-y. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources